Volume 21 Issue 2
Feb.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(2): 221-224
YANG Dan, HUANG Yu-li, XU Shu-nan. Relationship between Arg389Gly gene polymorphism and improved ventricular remodelling and clinical prognosis in patients with chronic heart failure[J]. Chinese Journal of General Practice, 2023, 21(2): 221-224. doi: 10.16766/j.cnki.issn.1674-4152.002850
Citation: YANG Dan, HUANG Yu-li, XU Shu-nan. Relationship between Arg389Gly gene polymorphism and improved ventricular remodelling and clinical prognosis in patients with chronic heart failure[J]. Chinese Journal of General Practice, 2023, 21(2): 221-224. doi: 10.16766/j.cnki.issn.1674-4152.002850
shu

Relationship between Arg389Gly gene polymorphism and improved ventricular remodelling and clinical prognosis in patients with chronic heart failure

doi: 10.16766/j.cnki.issn.1674-4152.002850

  • Department of Cardiovascular Medicine, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 sk2020A0351

  • Received Date: 2022-01-12
    Available Online: 2023-04-20
    Abstract
  •   Objective  To investigate the relationship between β1 adrenergic receptor Arg389Gly gene polymorphism and cardiac function changes and clinical prognosis in patients with chronic heart failure.  Methods  A total of 120 patients with chronic heart failure who were admitted in the First Affiliated Hospital of Bengbu Medical College from April 2020 to May 2021 were selected. Based on the Arg389Gly genotype, patients were divided into CC (43 cases), GC (56 cases) and GG (21 cases) groups. Clinical data were collected at admission, and patients were followed up for 6 months by outpatient or telephone after discharge and the changes of cardiac function and clinical prognosis of patients in 3 groups before and after drug treatment were analyzed.  Results  The frequency of the Arg389Gly genotype was in the following order: CC (35.8%), GC (46.7%) and GG (17.5%). After 6 months of follow-up, there were statistically significant differences in N-terminal pro-brain natriuretic peptide (NT-proBNP) decrease, left ventricular ejection fraction (LVEF) increase, left ventricular end diastolic dimension (LVDD) and left ventricular end-systolic diameter (LVDS) decrease among the three groups (all P < 0.05), and the improvement of CC group was significantly better than that of GG group (P < 0.017). The decrease of soluble growth stimulation expression gene 2 protein (sST2) in the three groups was statistically significant at 6 months follow-up (P=0.006), and the CC group was better than the GG group (P=0.014). During follow-up, a total of 44 patients had cardiac death, readmission caused by heart failure and malignant arrhythmia events. Log-rank test indicated that the incidence of endpoint events in the three groups was statistically significant (P=0.026). Kaplan-Meier curve indicated that the incidence of endpoint events in the CC group was lower than that in the GG group.  Conclusion  Arg389Gly gene polymorphism is associated with cardiac function changes and clinical prognosis in patients with chronic heart failure.

     

    • FullText(HTML)
  • loading
    • References(16)
  • [1]
    YANCY C W, JESSUP M, BOZKURT B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. Circulation, 2017, 136(6): 137-161.
    [2]
    DOIMO S, PAVAN D. Novelties in therapy of chronic heart failure[J]. Heart Fail Clin, 2021, 17(2): 255-262. doi: 10.1016/j.hfc.2021.01.006
    [3]
    OLIVER E, MAYOR F J R, D'OCON P. Beta-blockers: historical perspective and mechanisms of action[J]. Rev Esp Cardiol, 2019, 72(10): 853-862. doi: 10.1016/j.recesp.2019.02.023
    [4]
    中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004

    Heart failure Group, Chinese Society of Cardiology, Chinese Medical Doctor Association Heart Failure Professional Committee, Editorial Board of the Chinese Journal of Cardiovascular Diseases. Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. doi: 10.3760/cma.j.issn.0253-3758.2018.10.004
    [5]
    MCCRINK K A, BRILL A, JAFFERJEE M, et al. β1-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes[J]. Pharmacogenomics, 2016, 17(15): 1611-1620. doi: 10.2217/pgs-2016-0094
    [6]
    ROSSIGNOL P, HERNANDEZ A F, SOLOMON S D, et al. Heart failure drug treatment[J]. The Lancet, 2019, 393(10175): 1034-1044. doi: 10.1016/S0140-6736(18)31808-7
    [7]
    潘春奇, 菅颖, 倪斌, 等. 沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J]. 中华全科医学, 2020, 18(11): 1848-1850. doi: 10.16766/j.cnki.issn.1674-4152.001635

    PAN C Q, JIAN Y, NI B, et al. The effect of sacubitril/valsartan on myocardial injury and inflammatory factors in ischemic cardiomyopathy with reduced ejection fraction[J]. Chinese Journal of General Practice, 2020, 18(11): 1848-1850. doi: 10.16766/j.cnki.issn.1674-4152.001635
    [8]
    GAO X, WANG H, CHEN H. Impact of CYP2D6 and ADRB1 polymorphisms on heart rate of post-PCI patients treated with metoprolol[J]. Pharmacogenomics, 2017, 11. DOI: 10.2217/pgs-2017-0203.
    [9]
    THOMAS C D, JOHNSON J A. Pharmacogenetic factors affecting β-blocker metabolism and response[J]. Expert Opin Drug Metab Toxicol, 2020, 16(10): 953-964. doi: 10.1080/17425255.2020.1803279
    [10]
    BENCIVENGA L, LICCARDO D, NAPOLITANO C, et al. β-Adrenergic receptor signaling and heart failure: from bench to bedside[J]. Heart Fail Clin, 2019, 15(3): 409-419. doi: 10.1016/j.hfc.2019.02.009
    [11]
    PETROW V S, SMIRNOVA E A. The role of ADRB1 genes polymorphism in examined patients with chronic rheumatic heart disease[J]. Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med, 2019, 27(6): 962-966.
    [12]
    CORLETTO A, FROHLICH H, TAGER T, et al. Beta blockers and chronic heart failure patients: prognostic impact of a dose targeted beta blocker therapy vs. heart rate targeted strategy[J]. Clin Res Cardiol, 2018, 107(11): 1040-1049. doi: 10.1007/s00392-018-1277-4
    [13]
    PARIKH K S, FIUZAT M, DAVIS G, et al. Dose response of β-bockers in adrenergic receptor polymorphism genotypes[J]. Circ Genom Precis Med, 2018, 11(8): e002210. DOI: 10.1161/CIRCGEN.117.002210.
    [14]
    TAYLOR M R, SUN A Y, DAVIS G, et al. Race, common genetic variation, and therapeutic response disparities in heart failure[J]. JACC Heart Fail, 2014, 2(6): 561-572. doi: 10.1016/j.jchf.2014.06.010
    [15]
    ABOUEZZEDDINE O F, MCKIE P M, DUNLAY S M, et al. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction[J]. J Am Heart Assoc, 2017, 6(9): e002231. DOI: 10.1161/JAHA.117.002231.
    [16]
    AJAM T, AJAM S, DEVARAJ S, et al. Effect on mortality of higher versus lower β-blocker dose in patients with heart failure[J]. Am Cardiol, 2018, 122(6): 994-998. doi: 10.1016/j.amjcard.2018.05.038
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (146) PDF downloads(7) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return